Business Wire
20 Aug 2026, 03:06 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Amylyx Pharmaceuticals has priced an upsized public offering of 14,090,000 shares of common stock at $35.50 per share. — Public offerings typically create immediate downward pressure on share prices due to equity dilution.
-0.40Underwriters have been granted a 30-day option to purchase an additional 2,113,500 shares. — This represents a potential for further dilution, though the scale is smaller than the primary offering.
-0.10Which stocks this story touches
The company is successfully raising capital through an upsized public offering, indicating strong investor demand.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
